-
Something wrong with this record ?
Immunological examination of peripheral blood in patients with colorectal cancer compared to healthy controls
J. Spacek, M. Vocka, I. Netikova, H. Skalova, P. Dundr, B. Konopasek, E. Zavadova, P. Lubos,
Language English Country England, Great Britain
Document type Journal Article
Grant support
NV15-28188A
MZ0
CEP Register
Digital library NLK
Full text - Article
Source
NLK
Medline Complete (EBSCOhost)
from 2001-02-01 to 1 year ago
- MeSH
- Adenocarcinoma immunology MeSH
- B-Lymphocytes immunology MeSH
- Immunity, Cellular MeSH
- Killer Cells, Natural immunology MeSH
- CD4-Positive T-Lymphocytes immunology MeSH
- CD8-Positive T-Lymphocytes immunology MeSH
- Colorectal Neoplasms immunology MeSH
- Blood Circulation MeSH
- Middle Aged MeSH
- Humans MeSH
- Lymphocyte Count MeSH
- Neoplasm Staging MeSH
- Transforming Growth Factor beta1 blood MeSH
- Vascular Endothelial Growth Factor A blood MeSH
- Check Tag
- Middle Aged MeSH
- Humans MeSH
- Male MeSH
- Female MeSH
- Publication type
- Journal Article MeSH
BACKGROUND: The objective of this study was to investigate serum levels of immunosuppressive cytokines TGF beta 1 and VEGF and count of immune cells in peripheral blood in stage II and III colorectal cancer patients. METHODS: Blood samples were collected from 22 colorectal patients and 25 healthy controls before the start of treatment. All patients were examined by a clinical immunologist to exclude patients with immune disorders and autoimmune diseases. TGF beta 1 and VEGF were measured by ELISA, and anti-tumor cellular immunity cells (CD4, CD8, B cells, NK cells) were measured by flow cytometry. RESULTS: TGF beta 1 and VEGF plasma levels were significantly increased in stage II and III colorectal patients compared with control group (both p < 0.0001). A decrease in the cellular immunity was shown in the absolute numbers of cytotoxic T lymphocytes (CD8+ ; p = 0.0240), helper T lymphocytes (CD4+ ; p = 0.0019), and natural killer cells (CD16 + CD56+; p < 0.0001) in both stage II and stage III patients. On the contrary, B lymphocyte (CD19+) serum levels were increased in colon cancer patients (p < 0.0001) compared to the control group. CONCLUSIONS: Our results show peripheral blood levels of TGF beta and VEGF were significantly increased in colorectal patients and changes in cellular anticancer immunity in comparison to control group. These results will be compared with results from Immunoscore.
c Department of Pathology 1st Faculty of Medicine Charles University Praha Czech Republic
Department of Oncology 1st Faculty of Medicine Charles University Prague Czech Republic
References provided by Crossref.org
- 000
- 00000naa a2200000 a 4500
- 001
- bmc19000628
- 003
- CZ-PrNML
- 005
- 20201021092517.0
- 007
- ta
- 008
- 190107s2018 enk f 000 0|eng||
- 009
- AR
- 024 7_
- $a 10.1080/08820139.2018.1480030 $2 doi
- 035 __
- $a (PubMed)29924680
- 040 __
- $a ABA008 $b cze $d ABA008 $e AACR2
- 041 0_
- $a eng
- 044 __
- $a enk
- 100 1_
- $a Spacek, Jan $u a Department of Oncology, First Faculty of Medicine , Charles University , Prague , Czech Republic.
- 245 10
- $a Immunological examination of peripheral blood in patients with colorectal cancer compared to healthy controls / $c J. Spacek, M. Vocka, I. Netikova, H. Skalova, P. Dundr, B. Konopasek, E. Zavadova, P. Lubos,
- 520 9_
- $a BACKGROUND: The objective of this study was to investigate serum levels of immunosuppressive cytokines TGF beta 1 and VEGF and count of immune cells in peripheral blood in stage II and III colorectal cancer patients. METHODS: Blood samples were collected from 22 colorectal patients and 25 healthy controls before the start of treatment. All patients were examined by a clinical immunologist to exclude patients with immune disorders and autoimmune diseases. TGF beta 1 and VEGF were measured by ELISA, and anti-tumor cellular immunity cells (CD4, CD8, B cells, NK cells) were measured by flow cytometry. RESULTS: TGF beta 1 and VEGF plasma levels were significantly increased in stage II and III colorectal patients compared with control group (both p < 0.0001). A decrease in the cellular immunity was shown in the absolute numbers of cytotoxic T lymphocytes (CD8+ ; p = 0.0240), helper T lymphocytes (CD4+ ; p = 0.0019), and natural killer cells (CD16 + CD56+; p < 0.0001) in both stage II and stage III patients. On the contrary, B lymphocyte (CD19+) serum levels were increased in colon cancer patients (p < 0.0001) compared to the control group. CONCLUSIONS: Our results show peripheral blood levels of TGF beta and VEGF were significantly increased in colorectal patients and changes in cellular anticancer immunity in comparison to control group. These results will be compared with results from Immunoscore.
- 650 _2
- $a adenokarcinom $x imunologie $7 D000230
- 650 _2
- $a B-lymfocyty $x imunologie $7 D001402
- 650 _2
- $a krevní oběh $7 D001775
- 650 _2
- $a CD4-pozitivní T-lymfocyty $x imunologie $7 D015496
- 650 _2
- $a CD8-pozitivní T-lymfocyty $x imunologie $7 D018414
- 650 _2
- $a kolorektální nádory $x imunologie $7 D015179
- 650 _2
- $a ženské pohlaví $7 D005260
- 650 _2
- $a lidé $7 D006801
- 650 _2
- $a buněčná imunita $7 D007111
- 650 _2
- $a buňky NK $x imunologie $7 D007694
- 650 _2
- $a počet lymfocytů $7 D018655
- 650 _2
- $a mužské pohlaví $7 D008297
- 650 _2
- $a lidé středního věku $7 D008875
- 650 _2
- $a staging nádorů $7 D009367
- 650 _2
- $a transformující růstový faktor beta1 $x krev $7 D053773
- 650 _2
- $a vaskulární endoteliální růstový faktor A $x krev $7 D042461
- 655 _2
- $a časopisecké články $7 D016428
- 700 1_
- $a Vocka, Michal $u a Department of Oncology, First Faculty of Medicine , Charles University , Prague , Czech Republic.
- 700 1_
- $a Netikova, Irena $u b Department of Clinical Pharmacology and Pharmacy, First Faculty of Medicine , Charles University , Praha , Czech Republic.
- 700 1_
- $a Skalova, Helena $u c Department of Pathology, First Faculty of Medicine , Charles University , Praha , Czech Republic.
- 700 1_
- $a Dundr, Pavel $u c Department of Pathology, First Faculty of Medicine , Charles University , Praha , Czech Republic.
- 700 1_
- $a Konopasek, Bohuslav $u a Department of Oncology, First Faculty of Medicine , Charles University , Prague , Czech Republic.
- 700 1_
- $a Zavadova, Eva $u a Department of Oncology, First Faculty of Medicine , Charles University , Prague , Czech Republic.
- 700 1_
- $a Lubos, Petruzelka $u a Department of Oncology, First Faculty of Medicine , Charles University , Prague , Czech Republic.
- 773 0_
- $w MED00007245 $t Immunological investigations $x 1532-4311 $g Roč. 47, č. 7 (2018), s. 643-653
- 856 41
- $u https://pubmed.ncbi.nlm.nih.gov/29924680 $y Pubmed
- 910 __
- $a ABA008 $b sig $c sign $y a $z 0
- 990 __
- $a 20190107 $b ABA008
- 991 __
- $a 20201021092515 $b ABA008
- 999 __
- $a ok $b bmc $g 1364673 $s 1038751
- BAS __
- $a 3
- BAS __
- $a PreBMC
- BMC __
- $a 2018 $b 47 $c 7 $d 643-653 $e 20180620 $i 1532-4311 $m Immunological investigations $n Immunol Invest $x MED00007245
- GRA __
- $a NV15-28188A $p MZ0
- LZP __
- $a Pubmed-20190107
